EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Focal high‐intensity focused ultrasound therapy for localized prostate cancer: An interim analysis of the multinational FASST study

Sam Ladjevardi, Anna Ebner iD, Aleksandar Femic, Nicolai A Huebner, Shahrokh F Shariat, Simon Kraler iD, Rahel A Kubik-Huch iD, Rafaele C Ahlman, Michael Häggman, Lukas J Hefermehl

European Journal of Clinical Investigation · 2024

DOI: 10.1111/eci.14192 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Clinical Investigation, 2024. Verfasst von Sam Ladjevardi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Uppsala, Uppsala, Sweden. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostate-Specific Antigen. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

High‐intensity focused ultrasound (HIFU) emerged as a novel approach for the treatment of localized prostate cancer (PCa). However, prospective studies on HIFU‐related outcomes and predictors of treatment failure (TF) remain scarce. Materials and Methods We conducted a multinational prospective cohort study among patients undergoing HIFU therapy for localized, low‐ to intermediate‐risk PCa. Follow‐up data on serial prostate specific antigen (PSA), multi‐parametric magnetic resonance imaging (mpMRI), targeted/systematic biopsies, adverse events and functional outcomes were collected. The primary endpoint was TF, defined as histologically confirmed PCa requiring whole‐gland salvage treatment. Uni‐ and multi‐variable adjusted hazard ratios (HRs) were calculated using Cox proportional hazard regression models.

Results

At baseline, mean (standard deviation) age was 64.14 (7.19) years, with the majority of patients showing T‐stage 1 (73.9%) and International Society of Urological Pathology grading system Grade 2 (58.8%). PSA nadir (median, 1.70 ng/mL) was reached after 6 months. Of all patients recruited, 16% had clinically significant PCa, as confirmed by biopsy, of which 13.4% had TF. Notably, T‐stage and number of positive cores at initial biopsy were independent predictors of TF during follow‐up (HR [95% CI] 1.27 [1.02–1.59] and 5.02 [1.80–14.03], respectively). Adverse events were minimal (17% and 8% early and late adverse events, respectively), with stable or improved functional outcomes in the majority of patients.

Conclusions

This interim analysis of a multinational study on HIFU therapy for the management of low‐to‐intermediate‐risk PCa reveals good functional outcomes, minimal adverse events and low incidence of TF over the short‐term. Data on long‐term outcomes, specifically as it relates to oncological outcomes, are awaited eagerly.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProstate-Specific AntigenHumansMaleMiddle AgedAgedProspective StudiesUltrasound, High-Intensity Focused, TransrectalTreatment FailureProportional Hazards ModelsSalvage TherapyHigh-Intensity Focused Ultrasound AblationMultiparametric Magnetic Resonance ImagingNeoplasm GradingCohort Studies

Stichwörter der Autor:innen

focal therapyhigh intensity focused ultrasound therapylocalized prostate cancerprostate

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology, University of Uppsala, Uppsala, Sweden.
  • Department of Urology, Cantonal Hospital Baden, Baden, Switzerland.
  • Department of Urology, University Hospital Zurich, Zurich, Switzerland.
  • Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Working Group for Diagnostic imaging in Urology (ABDU), Austrian association of Urology (ÖGU), Vienna, Austria.
  • Department of urology, University of California Davis, Sacramento, California, USA.

ORCID-Profile: Anna Ebner, Simon Kraler, Rahel A Kubik-Huch

Zitieren

APA

Ladjevardi, S., Ebner, A., Femic, A., Huebner, N. A., Shariat, S. F., Kraler, S., Kubik-Huch, R. A., Ahlman, R. C., Häggman, M., & Hefermehl, L. J. (2024). Focal high‐intensity focused ultrasound therapy for localized prostate cancer: An interim analysis of the multinational FASST study. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.14192

Vancouver

Ladjevardi S, Ebner A, Femic A, Huebner NA, Shariat SF, Kraler S, et al. Focal high‐intensity focused ultrasound therapy for localized prostate cancer: An interim analysis of the multinational FASST study. European Journal of Clinical Investigation. 2024. doi:10.1111/eci.14192

BibTeX
@article{Ladjevardi2024,
  author = {Ladjevardi, Sam and Ebner, Anna and Femic, Aleksandar and Huebner, Nicolai A and Shariat, Shahrokh F and Kraler, Simon and Kubik-Huch, Rahel A and Ahlman, Rafaele C and Häggman, Michael and Hefermehl, Lukas J},
  title = {Focal high‐intensity focused ultrasound therapy for localized prostate cancer: An interim analysis of the multinational FASST study},
  journal = {European Journal of Clinical Investigation},
  year = {2024},
  doi = {10.1111/eci.14192}
}
Kostenlos starten →